In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Evaluation of the effectiveness of lisinicore and losartan in patients with chronic heart failure

Session Poster Session 3

Speaker Umida Kamilova

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Comorbidities
  • Session type : Poster Session

Authors : U Kamilova (Tashkent,UZ), Z Rasulova (Tashkent,UZ), D Masharipova (Tashkent,UZ), G Zakirova (Tashkent,UZ)

Authors:
U Kamilova1 , Z Rasulova1 , D Masharipova1 , G Zakirova2 , 1Republican specialized scientific-practical Medical Center Therapy and Medical Rehabilitation - Tashkent - Uzbekistan , 2Tashkent medical academy - Tashkent - Uzbekistan ,

Citation:

Purpose. To study the effect of lisinopril and losartan on the functional state of the kidneys of patients with I-III functional class (FC) of chronic heart failure (CHF), depending on the degree of renal dysfunction (RD).

Methods. A total of 223 patients with ischemic heart disease with I-III FC of CHF were examined, initially and after 6 months of treatment. The first group (I) consisted of 118 patients taking lisinopril as part of standard therapy; the second group (II) - 105 patients taking losartan. Also, all patients were divided into 2 groups depending on the estimated glomerular filtration rate (eGFR): 30 60 ml / min / 1,73m2 -156 patients (89 patients in group 1,67 patients in group 2).

Results. The nephroprotective effect of standard therapy with the inclusion of lisinopril or losartan was noted, with a significant decrease in the level of enzymes in the urine, as a sign of dysfunction of the tubular kidney apparatus, a decrease in creatinine, and an increase in GFR. In patients with CHF with a preserved eGFR> 60 ml / min / 1,73 m2 and moderate RD with eGFR = 59-45 ml / min / 1,73 m2, the use of standard lisinopril or losartan showed reliable nephroprotection. In patients with CHF with kidney dysfunction with 30> eGFR <45 ml / min / 1,73 m2, a significant improvement in renal dysfunction was observed in the group of patients taking standard therapy - losartan.

Conclusion. The results of our studies in patients with CHF showed that RD appeared at the subclinical stage, when the majority of patients do not have clinical signs of renal failure, which is also correlated with the findings of other researchers. According to many studies, the positive effect of ACE I and ARA is due to the fact that they reduce the initially high blood pressure in glomeruli of the kidneys, which stops the development of glomerulosclerosis

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are